Loading...
XKRX141080
Market cap1.89bUSD
Dec 24, Last price  
103,300.00KRW
1D
6.17%
1Q
3.30%
Jan 2017
191.40%
IPO
315.69%
Name

LegoChem Biosciences Inc

Chart & Performance

D1W1MN
XKRX:141080 chart
P/E
P/S
80.14
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
6.15%
Rev. gr., 5y
6.23%
Revenues
34.15b
+2.20%
16,655,491,62722,056,557,55025,240,301,76457,500,138,69049,393,701,59132,157,006,37933,412,042,60034,145,640,060
Net income
-73.70b
L+63.45%
-14,724,669,419-12,933,665,235-25,770,424,80713,586,123,504-6,986,261,219-23,391,227,602-45,091,793,579-73,703,570,470
CFO
-62.24b
L+772.19%
-13,038,914,847-8,213,201,730-12,758,192,50624,113,461,209-14,893,363,011-42,048,759,598-7,135,573,296-62,235,789,510
Earnings
Mar 12, 2025

Profile

LegoChem Biosciences, Inc. a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, and oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It offers its products in the forms of tablets and capsules. The Company also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. LegoChem Biosciences, Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.
IPO date
May 10, 2013
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
34,145,640
2.20%
33,412,043
3.90%
32,157,006
-34.90%
Cost of revenue
101,076,210
75,462,555
66,108,986
Unusual Expense (Income)
NOPBT
(66,930,570)
(42,050,512)
(33,951,980)
NOPBT Margin
Operating Taxes
(2,042,988)
(2,630,824)
2,868,198
Tax Rate
NOPAT
(64,887,583)
(39,419,688)
(36,820,178)
Net income
(73,703,570)
63.45%
(45,091,794)
92.77%
(23,391,228)
234.82%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,671,708)
3,387,096
3,264,167
BB yield
0.09%
-0.32%
-0.24%
Debt
Debt current
12,115,563
12,032,811
2,858,195
Long-term debt
1,325,308
432,808
9,410,352
Deferred revenue
5
263,352
Other long-term liabilities
3,680,823
2,983,476
4,102,719
Net debt
(103,824,608)
(180,797,317)
(197,332,716)
Cash flow
Cash from operating activities
(62,235,790)
(7,135,573)
(42,048,760)
CAPEX
(1,319,488)
(4,772,140)
(18,950,492)
Cash from investing activities
9,367,175
(16,169,444)
(43,944,020)
Cash from financing activities
(1,908,991)
3,198,783
171,292,115
FCF
(66,954,593)
(13,336,042)
(79,228,749)
Balance
Cash
99,925,153
168,337,660
179,935,397
Long term investments
17,340,325
24,925,275
29,665,866
Excess cash
115,558,196
191,592,334
207,993,413
Stockholders' equity
55,576,954
125,717,968
(91,017,086)
Invested Capital
108,969,071
108,999,261
366,163,103
ROIC
ROCE
EV
Common stock shares outstanding
28,404
24,363
24,125
Price
65,000.00
51.69%
42,850.00
-23.21%
55,800.00
-20.40%
Market cap
1,846,262,340
76.85%
1,043,951,122
-22.45%
1,346,172,154
-15.60%
EV
1,742,588,390
864,236,666
1,150,346,028
EBITDA
(62,258,632)
(37,932,499)
(30,902,840)
EV/EBITDA
Interest
528,260
285,751
68,765
Interest/NOPBT